UnitedHealth Group Incorporated (UNH) is a stock, not an ETF, and it carries unusually wide analyst coverage. The central target of $480 is the arithmetic mean of recent, individually attributed price targets, rounded from roughly $477, rather than any single firm's figure or a headline consensus.
Recent targets include Morgan Stanley at $531, JPMorgan at $524, RBC Capital at $498, Mizuho at $500, Bernstein at $500, Goldman Sachs at $490, Wells Fargo at $487, Evercore ISI at $480, Argus at $470, Raymond James at $450, Barclays at $440, Baird at $427, and TD Cowen at $402. For context, S&P Global's poll of 26 analysts shows an average of $476.64, with a low near $380 and a high of $531, closely matching this calculation.
Views differ sharply. More bullish firms emphasize a faster-than-expected Medicare Advantage and Optum Health recovery; more cautious names, including TD Cowen's Hold and Baird's Neutral, argue that near-term valuation already prices in much of the anticipated 2027–2028 earnings rebound. That wide $380-to-$531 spread is the key signal: the mean is useful, but it is not a guarantee.
UNH last closed near $394.15, giving it a market capitalization of roughly $353 billion and a 52-week range of about $255.97 to $461.62. Reaching $480 from $394 requires an advance of approximately 22%, a substantial move that would also carry the shares above their 52-week high.
The path would likely depend on sustained EPS (earnings per share) growth. The company beat third-quarter 2026 expectations and raised its full-year adjusted EPS guidance to at least $20.50, while management signaled that the 2027 consensus of roughly $22.63 may be conservative. At a forward P/E (price-to-earnings ratio) near 17, any re-rating toward a higher multiple, combined with earnings growth, is what would have to drive the move.
The most important resistance level is the 52-week high near $461.62; a push toward $480 would first require clearing that prior peak. Nearer term, the shares sit just below the psychologically significant $400 mark. On the downside, the 60-day moving average near $391 and the prior consolidation zone in the $370s are the first notable support levels, with deeper support in the $350 area. The long-term structure remains one of recovery from the 2025–2026 selloff rather than a fresh breakout.
Analyst price targets typically reflect a roughly 12-month research horizon, though individual firms frame their targets around different assumptions for 2027 and 2028 earnings and rate cycles. Key items to watch include quarterly earnings and guidance, Medicare Advantage rate notices, Star ratings updates, any developments in the Department of Justice investigation, Optum Health margin trends, and changes to analyst targets and ratings.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover new opportunities, keep tabs on existing positions, and spot shifting trends more efficiently than manual screening alone. For investors watching UNH's recovery, the signals offer a data-driven way to complement fundamental research with real-time technical context.
The $480 central target for UnitedHealth Group (UNH) is a calculated average of recent analyst price targets, not an official published consensus or a prediction. It implies a roughly 22% advance from the current price near $394, a substantial move that would take the stock to new 52-week highs. The case rests on raised guidance, expected Medicare Advantage and Optum margin recovery, and a below-average valuation, while the obstacles are regulatory risk, medical-cost pressure, and the argument that much of the recovery is already priced in. The wide $380-to-$531 analyst range underscores genuine disagreement, and investors should monitor earnings, rate notices, and the Department of Justice probe rather than treat any single target as a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, UNH has been closely correlated with ELV. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is a high statistical probability that if UNH jumps, then ELV could also see price increases.